It is noteworthy that BRCA1 and FANCD2 mutation carriers commonly have KRT14-positive breast tumors [60, 61] and among sporadic breast cancer patients those with KRT14-positive tumors have markedly poorer prognosis than the patients with KRT14-negative tumors [61]. This evidence concerns the gene KRT14 and breast carcinoma.